Share
Save
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Study details:
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements. Eligible patients will be randomized on a 1:1 basis to the following study arms:. * Patients will receive futibatinib at an oral dose of 16 mg, administered daily (QD) on every day of a 21-day cycle.
* Patients will receive futibatinib at an oral dose of 20 mg, administered daily (QD) on every day of a 21-day cycle. Patients may continue to receive continuous futibatinib until documentation of progressive disease (PD) per RECIST 1. 1, or until other withdrawal criteria are met, whichever comes first.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 18 and older
Healthy volunteers accepted : No
Gender eligible for study: All
Things to know
Study dates
Study start: 2023-07-05
Primary completion: 2025-06-01
Study completion finish: 2026-06-01
Study type
TREATMENT
Phase
PHASE2
Trial ID
NCT05727176
Intervention or treatment
DRUG: TAS-120
Conditions
- • Advanced Cholangiocarcinoma
- • FGFR2 Fusions
- • Gene Rearrangement
Find a site
Closest Location:
St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
Research sites nearby
Select from list below to view details:
St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
Sydney, New South Wales, Australia
Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center
Melbourne, Victoria, Australia
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: Treatment Arm A
| DRUG: TAS-120
|
EXPERIMENTAL: Treatment Arm B
| DRUG: TAS-120
|
What is the study measuring?
Primary outcome
| Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
|---|---|---|
| ORR by independent central review | defined as the proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST 1.1), based on ICR | 12 months after the study completion |
Secondary outcome
| Secondary Outcome Measure | Secondary Outcome Description | Secondary Outcome Time Frame |
|---|---|---|
| DoR by independent review | defined as time from the first documentation of response to the first documentation of objective tumor progression by ICR (per RECIST 1.1) or death due to any cause, whichever occurs first | up to 12 months after the study completion |
| PFS by independent review | defined as the time from date of randomization to the date of documentation of disease progression by ICR per RECIST (version 1.1, 2009) or date of death, whichever comes first | up to 12 months after the study completion |
| ORR per Investigator assessment | defined as proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST v1.1). | up to 12 months after the study completion |
| DoR per Investigator assessment | defined as time from the first documentation of response to the first documentation of objective tumor progression or death due to any cause, whichever occurs first | up to 12 months after the study completion |
| PFS per Investigator assessment | defined as the time from date of randomization to the date of disease progression based on Investigator assessment of radiographic images or death, whichever occurs first | up to 12 months after the study completion |
| OS | defined as the time from the date of randomization until the date of death due to any cause. | up to 12 months after the study completion |
| Treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0 | Safety will be assessed based on reported AEs (including SAEs), graded by CTCAE V5.0. including serious adverse events (SAEs) and dose modifications. | up to 12 months after the study completion |
| Change from Baseline in Quality of life as assessed by EORTC QLQ-C30 | Change from Baseline in quality of life as assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score | up to 12 months after the study completion |
| Change from Baseline in Quality of life as assessed by EuroQol-5D (EQ-5D ) | Change from Baseline in Quality of Life as Assessed by European Quality of Life - 5 Dimensions-3 Levels (EQ-5D-3L) Scale Score. | up to 12 months after the study completion |
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!